Back to today’s briefing

Story perspectives

Vertex CEO Drives Breakthroughs in Non-Opioid Pain Relief and Gene Therapy

5/9/2025

50 6

Summary

Story summary

Dr. Reshma Kewalramani, CEO of Vertex Pharmaceuticals, is revolutionizing medicine with her leadership. She has championed the approval of Journavx, a historic non-opioid pain reliever, and secured FDA nods for innovative CRISPR gene therapies targeting sickle cell disease and beta thalassemia, alongside advancements in cystic fibrosis treatment, all aimed at enhancing human health.

1 of 1

Story summary

Dr. Reshma Kewalramani, CEO of Vertex Pharmaceuticals, is revolutionizing medicine with her leadership. She has championed the approval of Journavx, a historic non-opioid pain reliever, and secured FDA nods for innovative CRISPR gene therapies targeting sickle cell disease and beta thalassemia, alongside advancements in cystic fibrosis treatment, all aimed at enhancing human health.